Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AVENTYL vs AMITRIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nortriptyline, the active ingredient, inhibits the reuptake of norepinephrine and serotonin in the central nervous system, potentiating their effects. It also has anticholinergic and antihistaminergic properties.
Amitriptyline inhibits the reuptake of serotonin and norepinephrine, thereby increasing their synaptic concentrations. It also blocks histamine H1, alpha-1 adrenergic, and muscarinic receptors.
Major depressive disorder (endogenous depression)
Major depressive disorder,Neuropathic pain,Fibromyalgia,Migraine prophylaxis,Chronic tension-type headache,Insomnia (off-label),Irritable bowel syndrome (off-label)
Adults: 25 mg orally 3 to 4 times daily, maximum 150 mg/day.
Adults: Initial 25 mg PO once daily at bedtime, increase by 25 mg every 3-7 days as tolerated to typical maintenance 75-150 mg/day PO divided doses or single dose at bedtime. Maximum 300 mg/day.
Terminal elimination half-life: 19-24 hours; requires 4-6 days to reach steady state.
Terminal elimination half-life: 15–25 hours (mean 20 h); may extend to >40 h in elderly or hepatic impairment.
Extensively metabolized in the liver by cytochrome P450 enzymes (CYP2D6, CYP1A2, CYP2C19) via hydroxylation, N-demethylation, and N-oxidation; active metabolite: 10-hydroxynortriptyline. Metabolites are conjugated and excreted in urine.
Hepatic, primarily via CYP2D6 and CYP3A4, with contributions from CYP1A2 and CYP2C19. Amitriptyline is metabolized to nortriptyline (active) and other metabolites.
Renal (30% as unchanged drug and metabolites); biliary/fecal (70% as metabolites)
Renal: ~70% as metabolites, <5% unchanged; fecal: ~30% via bile.
90-95% bound primarily to albumin.
90–95% bound to albumin and alpha-1-acid glycoprotein.
15-30 L/kg; indicates extensive tissue penetration.
Vd: 15–30 L/kg; extensive tissue distribution, including CNS.
Oral: 30-60% due to first-pass metabolism.
Oral: 30–60% due to first-pass metabolism.
GFR 10-50 m L/min: administer 50-75% of normal dose; GFR <10 m L/min: administer 50% of normal dose or every 12 hours.
GFR 30-59 m L/min: Reduce dose by 50%. GFR 15-29 m L/min: Reduce dose by 75%. GFR <15 m L/min: Contraindicated. Hemodialysis: Not dialyzable; avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated or reduce dose by 75% with monitoring.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Use contraindicated or reduce dose by 75% with extreme caution.
Children 6-12 years: 10-30 mg/day in divided doses; >12 years: 25-50 mg/day in divided doses, maximum 100 mg/day. Weight-based: 1-2 mg/kg/day.
Children ≥12 years: Initial 25-50 mg/day PO, increase gradually to 100 mg/day in divided doses. Children 6-11 years: 1-3 mg/kg/day PO in divided doses, not to exceed 100 mg/day. Not recommended under 6 years.
Initial dose 10-25 mg/day in divided doses, titrate slowly to maximum 100 mg/day; use with caution due to anticholinergic effects.
Initial 10-25 mg PO at bedtime, with gradual titration. Maintenance often 50-100 mg/day. Monitor for orthostatic hypotension, falls, and anticholinergic effects.
Antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders. Nortriptyline is not approved for use in pediatric patients.
Amitriptyline is not approved for use in pediatric patients. Clinical worsening and suicide risk: Monitor for clinical worsening, suicidality, or unusual changes in behavior during initial therapy. Serotonin syndrome: Serotonin syndrome has been reported with SSRIs and SNRIs.
Suicidality: Monitor for worsening depression and suicidal thoughts, especially in young adults.,Cardiotoxicity: Risk of QT prolongation, arrhythmias, and sudden death; use with caution in patients with cardiovascular disease.,Serotonin syndrome: Risk when used with other serotonergic drugs.,Anticholinergic effects: Use caution in patients with prostatic hypertrophy, narrow-angle glaucoma, or urinary retention.,Seizures: May lower seizure threshold.,Electroconvulsive therapy (ECT): Avoid concomitant use.,Hepatic impairment: Use with caution; metabolism may be reduced.,Hyperthyroidism: May potentiate cardiac toxicity.
Suicidality in children, adolescents, and young adults; serotonin syndrome; activation of mania/hypomania; seizures; angle-closure glaucoma; urinary retention; cardiovascular effects (QT prolongation, arrhythmias); impaired cognitive/motor performance.
Hypersensitivity to nortriptyline or any component of the formulation.,Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing an MAOI.,Acute recovery phase after myocardial infarction.,Concomitant use with cisapride, due to risk of QT prolongation.
Hypersensitivity to amitriptyline or any component; concomitant use with MAOIs or within 14 days of MAOI use; recent myocardial infarction; during acute recovery phase after MI; concomitant use with cisapride.
Avoid tyramine-rich foods (aged cheeses, cured meats, sauerkraut, soy products, tap beers) as concomitant use with MAOIs is contraindicated. However, nortriptyline itself has minimal tyramine interaction. Grapefruit juice may increase nortriptyline levels; avoid or limit intake. High-fiber foods may reduce absorption; take with a full glass of water.
Avoid grapefruit and grapefruit juice as they may increase serum levels of amitriptyline. Limit tyramine-rich foods (aged cheeses, cured meats, fermented products) if taking MAOIs concurrently (contraindicated). Alcohol consumption may enhance sedative effects and is not recommended. High-fat meals may delay absorption but do not significantly alter overall exposure.
First trimester: Limited human data, animal studies show no consistent teratogenicity; avoid due to risk of fetal tachycardia. Second/third trimester: Risk of neonatal withdrawal (irritability, feeding disorders) and anticholinergic effects (ileus, tachycardia).
First trimester: Possible increased risk of cardiovascular malformations (OR ~1.2-1.5). Second/third trimester: Risk of neonatal withdrawal syndrome (irritability, feeding difficulties) and direct toxic effects (tachycardia, urinary retention). Late third trimester: Possible persistent pulmonary hypertension of the newborn (PPHN) with SSRI-like effects, though data limited for tricyclics.
Excreted in human milk; M/P ratio unknown. Limited data suggests low levels; use with caution, monitor infant for sedation and anticholinergic effects.
M/P ratio approximately 1.0-1.5. Excreted in breast milk in low amounts. Infant serum levels are usually subtherapeutic but cases of drowsiness, irritability reported. Use with caution; monitor infant for sedation and feeding difficulties. American Academy of Pediatrics considers compatible with breastfeeding if infant is healthy and full-term.
Increased hepatic metabolism in pregnancy may require dose adjustment; start at low end of dosing range, titrate based on response and tolerability.
Due to increased plasma volume and hepatic metabolism in pregnancy, lower serum concentrations may occur. Monitor clinical response; dose adjustments may be needed but no standard guidelines. Use lowest effective dose. Taper if discontinuing to avoid withdrawal.
Aventyl (nortriptyline) is a secondary amine tricyclic antidepressant with less anticholinergic and sedative effects than tertiary amines like amitriptyline. It exhibits a narrow therapeutic window; therapeutic plasma levels are 50-150 ng/m L. Use with caution in patients with cardiovascular disease due to risk of QT prolongation. Avoid abrupt discontinuation to prevent withdrawal-like symptoms. Monitoring of plasma levels is recommended in elderly and those with hepatic impairment.
For neuropathic pain, start at 10-25 mg at bedtime; titrate slowly to reduce sedative effects. Monitor QTc interval at baseline and with dose increases, especially in patients with cardiac risk factors. Anticholinergic effects (dry mouth, constipation) are common; consider prophylactic stool softeners. Avoid abrupt discontinuation; taper over 2-4 weeks to prevent withdrawal symptoms.
Take exactly as prescribed; do not adjust dose without consulting your doctor.,May cause drowsiness or dizziness; avoid driving until you know how it affects you.,Avoid alcohol and other CNS depressants.,Report any signs of serotonin syndrome (agitation, hallucinations, fever) or suicidal thoughts.,May take 2-4 weeks to see full therapeutic effect.,Do not stop abruptly; taper under medical supervision to avoid withdrawal symptoms.,Store at room temperature away from moisture and light.
Take exactly as prescribed, usually once daily at bedtime due to drowsiness.,Do not stop suddenly; taper under doctor's guidance to avoid nausea, headache, or insomnia.,Avoid alcohol and other CNS depressants (e.g., sedatives, opioids) as they increase sedation risk.,Report any signs of serotonin syndrome (e.g., agitation, hallucinations, rapid heart rate) or cardiac symptoms (e.g., palpitations, fainting).,May cause dry mouth, constipation, blurred vision; use sugar-free gum, hydrate, and consider fiber supplements.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AVENTYL vs AMITRIL, answered by our medical review team.
AVENTYL is a Tricyclic Antidepressant that works by Nortriptyline, the active ingredient, inhibits the reuptake of norepinephrine and serotonin in the central nervous system, potentiating their effects. It also has anticholinergic and antihistaminergic properties.. AMITRIL is a Tricyclic Antidepressant that works by Amitriptyline inhibits the reuptake of serotonin and norepinephrine, thereby increasing their synaptic concentrations. It also blocks histamine H1, alpha-1 adrenergic, and muscarinic receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AVENTYL and AMITRIL depend on the specific clinical indication. These are both Tricyclic Antidepressant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AVENTYL is: Adults: 25 mg orally 3 to 4 times daily, maximum 150 mg/day.. The standard adult dose of AMITRIL is: Adults: Initial 25 mg PO once daily at bedtime, increase by 25 mg every 3-7 days as tolerated to typical maintenance 75-150 mg/day PO divided doses or single dose at bedtime. Maximum 300 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AVENTYL and AMITRIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AVENTYL is classified as Category C. First trimester: Limited human data, animal studies show no consistent teratogenicity; avoid due to risk of fetal tachycardia. Second/third trimester: Risk of neonatal withdrawal (. AMITRIL is classified as Category C. First trimester: Possible increased risk of cardiovascular malformations (OR ~1.2-1.5). Second/third trimester: Risk of neonatal withdrawal syndrome (irritability, feeding difficul. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.